Matches in SemOpenAlex for { <https://semopenalex.org/work/W4246597360> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- W4246597360 abstract "Abstract Background Regorafenib has shown promising results as a second-line therapy for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib. Although several data regarding the efficacy of sequential therapy with sorafenib and that of regorafenib in real-life, specific inflammation markers for predicting the prognosis have not been studied. This study aimed to investigate prognostic value of systemic inflammatory markers in patients with HCC who received sorafenib-regorafenib sequential therapy. Methods We retrospectively analyzed medical data of patients who received regorafenib for the treatment of HCC after sorafenib failure. Progression free survival (PFS) and overall survival (OS) were assessed using the Kaplan–Meier survival curves. Univariate and multivariate analyses were performed to analyze the factors associated with survival. Results A total of 58 patients who received at least one dose of regroafenib and fulfilled the eligibility criteria, good performance status (Eastern Cooperative Oncology Group [ECOG] 0–1) and preserved liver function (Child-Pugh-A), were included in the analysis. The median PFS was 3 months (95% confidence interval [CI] = 0.981–5.019) and the median OS was 8 months (95% CI = 5.761–10.239). Elevated systemic immune-inflammation index (SII ≥ 340) was independently associated with poor OS. In multivariate analysis, the SII (hazard ratio [HR] = 2.211, 95% CI = 1.089–4.489, P = 0.028) and alpha-fetoprotein (AFP) (HR = 2.750, 95% CI = 1.259–6.010, P = 0.011) were independent predictors of OS. Conclusion Elevated SII is associated with poor OS in patients with HCC who received sequential therapy with sorafenib and regorafenib. In addition, when selecting a treatment strategy, the SII can be used in combination with the AFP level as a promising prognostic tool for HCC." @default.
- W4246597360 created "2022-05-12" @default.
- W4246597360 creator A5016539137 @default.
- W4246597360 creator A5018742918 @default.
- W4246597360 creator A5031127358 @default.
- W4246597360 date "2020-07-24" @default.
- W4246597360 modified "2023-10-14" @default.
- W4246597360 title "Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma" @default.
- W4246597360 doi "https://doi.org/10.21203/rs.3.rs-46929/v1" @default.
- W4246597360 hasPublicationYear "2020" @default.
- W4246597360 type Work @default.
- W4246597360 citedByCount "0" @default.
- W4246597360 crossrefType "posted-content" @default.
- W4246597360 hasAuthorship W4246597360A5016539137 @default.
- W4246597360 hasAuthorship W4246597360A5018742918 @default.
- W4246597360 hasAuthorship W4246597360A5031127358 @default.
- W4246597360 hasBestOaLocation W42465973601 @default.
- W4246597360 hasConcept C121608353 @default.
- W4246597360 hasConcept C126322002 @default.
- W4246597360 hasConcept C143998085 @default.
- W4246597360 hasConcept C144301174 @default.
- W4246597360 hasConcept C207103383 @default.
- W4246597360 hasConcept C2776248978 @default.
- W4246597360 hasConcept C2778019345 @default.
- W4246597360 hasConcept C2778695046 @default.
- W4246597360 hasConcept C38180746 @default.
- W4246597360 hasConcept C44249647 @default.
- W4246597360 hasConcept C526805850 @default.
- W4246597360 hasConcept C71924100 @default.
- W4246597360 hasConcept C90924648 @default.
- W4246597360 hasConceptScore W4246597360C121608353 @default.
- W4246597360 hasConceptScore W4246597360C126322002 @default.
- W4246597360 hasConceptScore W4246597360C143998085 @default.
- W4246597360 hasConceptScore W4246597360C144301174 @default.
- W4246597360 hasConceptScore W4246597360C207103383 @default.
- W4246597360 hasConceptScore W4246597360C2776248978 @default.
- W4246597360 hasConceptScore W4246597360C2778019345 @default.
- W4246597360 hasConceptScore W4246597360C2778695046 @default.
- W4246597360 hasConceptScore W4246597360C38180746 @default.
- W4246597360 hasConceptScore W4246597360C44249647 @default.
- W4246597360 hasConceptScore W4246597360C526805850 @default.
- W4246597360 hasConceptScore W4246597360C71924100 @default.
- W4246597360 hasConceptScore W4246597360C90924648 @default.
- W4246597360 hasLocation W42465973601 @default.
- W4246597360 hasLocation W42465973602 @default.
- W4246597360 hasOpenAccess W4246597360 @default.
- W4246597360 hasPrimaryLocation W42465973601 @default.
- W4246597360 hasRelatedWork W2072645058 @default.
- W4246597360 hasRelatedWork W2338961863 @default.
- W4246597360 hasRelatedWork W2592068656 @default.
- W4246597360 hasRelatedWork W2770409748 @default.
- W4246597360 hasRelatedWork W2938267598 @default.
- W4246597360 hasRelatedWork W2981944047 @default.
- W4246597360 hasRelatedWork W3215463326 @default.
- W4246597360 hasRelatedWork W4283321516 @default.
- W4246597360 hasRelatedWork W4361955616 @default.
- W4246597360 hasRelatedWork W4361955619 @default.
- W4246597360 isParatext "false" @default.
- W4246597360 isRetracted "false" @default.
- W4246597360 workType "article" @default.